The interventional cardiology devices market is a multi-billion-dollar market which includes, but is not limited to, drug-eluting stents, catheters, bare-metal stents, guidewires, and percutaneous transluminal coronary angioplasty. The intervention cardiology devices market provides treatment for a range of cardiovascular diseases including coronary artery disease, peripheral vascular disease, and heart valve disease. The global interventional cardiology devices market is anticipated to expand at a CAGR of 6.04% during the 2018-2023 period, and will reach a value of USD 15.43 Bn by 2023. Rising incidence of cardiovascular diseases, along with the adoption of minimally invasive surgeries is expected to drive the interventional cardiology devices market during the forecast period.
Segmentation based on product type
Based on product type, the drug-eluting stents segment contributed the highest revenue in 2018, by replacing the bare-metal stents market, owing to major technological advancements. The segment is anticipated to register a CAGR of 5.71% during the 2018-2023 period, to reach USD 6.71 Bn by 2023. Catheters being the major medium of interventional cardiology procedures, its segment holds a market share of ~27%. The segment is expected to expand at the highest CAGR (7.02%) during the forecast period.
Regional insights
North America accounted for ~38% of the total revenue of the interventional cardiology devices market in 2018, followed by Asia-Pacific (~27%). The Asia-Pacific region is anticipated to expand at the highest CAGR (6.94%) during the forecast period, followed by Latin America, and the Middle East and Africa, expanding at CAGRs of 6.54% and 6.29% respectively. Most of Asia-Pacific’s growth is estimated to come from China, Japan, and India due to the increasing incidence of cardiovascular diseases and rising number of diabetic patients.
Companies profiled
Abbott Laboratories
Boston Scientific Corporation
Medtronic
Terumo Corporation
Edwards Lifesciences Corporation
Becton Dickinson
Johnson & Johnson
B. Braun Melsungen
Teleflex Incorporated
MicroPort Scientific Corporation
Chapter 1: Executive Summary
1.1. Market scope and segmentation
1.2. Key questions answered in the study
1.3. Executive summary
Chapter 2: Introduction
2.1. Market definitions
2.2. Market trends
2.3. Market drivers
2.4. Market challenges
2.5. Revenue based on product type - (USD Bn) (2018)
2.6. Value chain analysis of the global interventional cardiology devices market
Chapter 3: Global interventional cardiology devices market overview
3.1. Market overview
3.1.1. Global historical market revenue (USD Bn) (2016-2017)
3.1.2. Global forecast market revenue (USD Bn) (2018-2023)
3.1.3. Geography-wise market revenue (USD Bn) (2018 and 2023)
Chapter 4: Global interventional cardiology devices market - based on product type
4.1. Drug-eluting stents market
4.1.1. Revenue - (2015, 2018 and 2023) (USD Bn)
4.1.2. Trends
4.1.3. Drivers
4.2. Catheters market
4.2.1. Revenue - (2015, 2018 and 2023) (USD Bn)
4.2.2. Trends
4.2.3. Drivers
4.3. Bare-metal stents market
4.3.1. Revenue - (2015, 2018 and 2023) (USD Bn)
4.3.2. Trends
4.3.3. Drivers
4.4. Guidewires market
4.4.1. Revenue - (2015, 2018 and 2023) (USD Bn)
4.4.2. Trends
4.4.3. Drivers
4.5. Other interventional cardiology devices market
4.5.1. Revenue - (2015, 2018 and 2023) (USD Bn)
4.5.2. Trends
4.5.3. Drivers
Chapter 5: Global interventional cardiology devices market - based on regions
5.1. North America
5.1.1. Overview
5.1.2. Revenue - (2015-2023) (USD Bn)
5.1.3. Key highlights
5.2. Europe
5.2.1. Overview
5.2.2. Revenue - (2015-2023) (USD Bn)
5.2.3. Key highlights
5.3. Asia-Pacific
5.3.1. Overview
5.3.2. Revenue - (2015-2023) (USD Bn)
5.3.3. Key highlights
5.4. Latin America
5.4.1. Overview
5.4.2. Revenue - (2015-2023) (USD Bn)
5.4.3. Key highlights
5.5. The Middle East and Africa
5.5.1. Overview
5.5.2. Revenue - (2015-2023) (USD Bn)
5.5.3. Key highlights
Chapter 6: Market share of companies
6.1. Companies’ share in the global interventional cardiology devices market
Chapter 7: Competitive landscape
7.1. Abbott Laboratories
7.1.1. Company snapshot
7.1.2. Key financials
7.1.3. Business description and major products
7.1.4. Global presence
7.1.5. Major initiatives
7.1.6. Growth strategies
Note: Similar information areas will be covered for the competitors
7.2. Boston Scientific Corporation
7.3. Medtronic
7.4. Terumo Corporation
7.5. Edwards Lifesciences Corporation
7.6. Becton Dickinson
7.7. Johnson & Johnson
7.8. B. Braun Melsungen
7.9. Teleflex Incorporated
7.10. MicroPort Scientific Corporation
Chapter 8: Conclusion
8.1. Conclusion
Chapter 9: Appendix
9.1. List of tables
9.2. Assumptions
9.3. Research methodology
9.4. About Research On Global Markets
9.5. Disclaimer
The interventional cardiology devices market is a multi-billion-dollar market which includes, but is not limited to, drug-eluting stents, catheters, bare-metal stents, guidewires, and percutaneous transluminal coronary angioplasty. The intervention cardiology devices market provides treatment for a range of cardiovascular diseases including coronary artery disease, peripheral vascular disease, and heart valve disease. The global interventional cardiology devices market is anticipated to expand at a CAGR of 6.04% during the 2018-2023 period, and will reach a value of USD 15.43 Bn by 2023. Rising incidence of cardiovascular diseases, along with the adoption of minimally invasive surgeries is expected to drive the interventional cardiology devices market during the forecast period.
Segmentation based on product type
Based on product type, the drug-eluting stents segment contributed the highest revenue in 2018, by replacing the bare-metal stents market, owing to major technological advancements. The segment is anticipated to register a CAGR of 5.71% during the 2018-2023 period, to reach USD 6.71 Bn by 2023. Catheters being the major medium of interventional cardiology procedures, its segment holds a market share of ~27%. The segment is expected to expand at the highest CAGR (7.02%) during the forecast period.
Regional insights
North America accounted for ~38% of the total revenue of the interventional cardiology devices market in 2018, followed by Asia-Pacific (~27%). The Asia-Pacific region is anticipated to expand at the highest CAGR (6.94%) during the forecast period, followed by Latin America, and the Middle East and Africa, expanding at CAGRs of 6.54% and 6.29% respectively. Most of Asia-Pacific’s growth is estimated to come from China, Japan, and India due to the increasing incidence of cardiovascular diseases and rising number of diabetic patients.
Companies profiled
Abbott Laboratories
Boston Scientific Corporation
Medtronic
Terumo Corporation
Edwards Lifesciences Corporation
Becton Dickinson
Johnson & Johnson
B. Braun Melsungen
Teleflex Incorporated
MicroPort Scientific Corporation
